MET exon 14 skipping
A specific MET change that opens the MET inhibitor category in lung cancer.
Parent marker: MET
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Clinical meaning
This change makes the MET protein more stable so that growth signals continue. This group is addressed with selective MET inhibitors.
How this finding appears in a report
Discovered through DNA or RNA sequencing; some panels need to be specifically designed to detect these types of changes.
When therapy stops working
Secondary changes in the MET kinase domain or activation of other pathways may occur following therapy.
What needs verification
- Complete variant name as written in the laboratory report.
- Examination methods and types of samples used.
- Examination dates were compared with ongoing therapy.
Marker context: MET
MET exon 14 skipping is generally discussed as a group that can be directed to MET inhibitors. MET amplification requires attention to the level of amplification and is often more complex, because it is also related to resistance.
A negative result does not always mean absent
Summary
- Gen
- MET
- Variant
- MET exon 14 skipping
- Alteration type
- Mutation
- Discussed in
- Lung Cancer
- Updated
- 2026-09-10
Other names in reports
METex14
Drugs discussed
Treatment categories
Sources
- NCI Dictionary of Cancer Terms(lembaga)
- ClinicalTrials.gov(registry)
Clinical trials
Studies mentioning marker MET
Filtered from public study descriptions. Access status and site readiness remain unverified.
NCT01639508Phase 2Combination regimen
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
Lung Cancer | biomarker: ROS1, MET, RET, NTRK
United States7 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker ROS1.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT01639508Not verified
NCT04928846Phase 3Combination regimen
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Lung Cancer | biomarker: EGFR, MET | Chemotherapy
United States, Argentina, Australia +29317 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker EGFR, the treatment category is Chemotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT04928846Not verified
NCT06106802Phase 2Targeted therapy
Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
Lung Cancer | biomarker: EGFR, MET | Targeted therapy
South Korea1 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker EGFR, the treatment category is Targeted therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06106802Not verified
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- MET
Biomarker
Reason: Related through a biomarker
- Lung Cancer
Cancer type
Reason: Related to this page
- Capmatinib
Drug
Reason: Related to this page
- Crizotinib
Drug
Reason: Related to this page
- Targeted therapy
Treatment category
Reason: Related to this page
- Savolitinib
Drug
Reason: Related to this page
To check
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.